Autologous transplantation in CLL patients with B and C Binet stages: Final results of the prospective randomized GOELAMS LLC 98 trial

Bone Marrow Transplantation

Volumn 47, Issue 4, 2012, Pages 542-548

  Brion, A ^a   Mahe B ^b   Kolb, B ^c   Audhuy, B ^d   Colombat, P ^e   Maisonneuve, H ^f   Foussard, C ^g   Bureau, A ^a   Ferrand, C ^a   Lesesve, J F ^h   Bene M C ⁱ   Feugier, P ^h  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c REIMS UNIVERSITY HOSPITAL   (France)

^d Service d'Hématologie   (France)

^e UNIVERSITY HOSPITAL OF TOURS   (France)

^f CENTRE HOSPITALIER   (France)

^g ANGERS UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF NANCY   (France)

ⁱ UNIVERSITÉ DE LORRAINE   (France)

Author keywords

autologous; CLL; transplantation

Indexed keywords

CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; ASPERGILLOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHOLESTASIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTERMETHOD COMPARISON; LEUKEMIA RELAPSE; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PHLEBITIS; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEPTIC SHOCK; SURVIVAL TIME; TREATMENT DURATION; TREATMENT PLANNING; WHOLE BODY RADIATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 84859472894     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.117     Document Type: Article

References (34)

1. Mauro FR, Foa R, Giannarelli D, Cordone I, Crescenzi S, Pescarmona E et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 1999; 94: 448-454. (Pubitemid 29323859)
2. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847. (Pubitemid 29430399)
3. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854. (Pubitemid 29430400)
4. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916. (Pubitemid 32064784)
5. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750-1757.
6. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079-4088. (Pubitemid 46211313)
7. Byrd CJ, Peterson BL, Morrisson VA, Park K, Jacobson R, Hoke E et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lympho-cytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101: 6-14. (Pubitemid 36025880)
8. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174.
9. Dreger P, Stilgenbauer S, Benner A, Ritgen M, Krober A, Kneba M et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood 2004; 103: 2850-2858. (Pubitemid 38393051)
10. Gribben JG, Zahrieh D, Stephans C, Bartlett-Pandite L, Alyea E, Fisher D et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005; 106: 4389-4396. (Pubitemid 41775953)
11. Michallet M, Dreger P, Sutton L, Brand R, Richards S, Van Os M et al. Autologous stem cell transplantation in chronic lymphocytic leukemia: results of an European intergroup randomized trial comparing autografting versus observation. Blood 2010; 117: 1516-1521.
12. Cheson BD, Benett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997. (Pubitemid 26189840)
13. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate analysis. Cancer 1981; 48: 198-206. (Pubitemid 11064396)
14. Dreger P, Monserrat E. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 2002; 16: 985-992. (Pubitemid 34618837)
15. Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B et al. Randomized comparison of fludarabine, CAP, and CHOP in 938 untreated stage B and C chronic lymphocytic leukemia. Blood 2001; 98: 2319-2325.
16. Van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immuno-globulin and T-cell receptor gene recombination in suspect lymphoproliferations: report of the biomed-2 concerted action BMH4-CT98-3936. Leukemia 2003; 17: 2257-2317. (Pubitemid 38072572)
17. Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que TH et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8: 1640-1645. (Pubitemid 24323778)
18. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF et al. Assessment of fludarabine plus cyclopho-sphamide for patients with chronic lymphocytic leukemia (The LFR CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230-239. (Pubitemid 47069536)
19. Knauf W, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R et al. Phase III randomized study of bendamus-tine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia. J Clin Oncol 2009; 27: 4378-4384.
20. Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukaemia. J Clin Oncol 2007; 25: 5616-5623.
21. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885-891. (Pubitemid 43156283)
22. Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007; 25: 793-798. (Pubitemid 350002879)
23. Provan D, Brtlett-Pandite L, Zwicky C, Neuberg D, Mad-docks A, Corradini P et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996; 88: 2228-2235. (Pubitemid 26307926)
24. Milligan DW, Fernandes S, Dasgupta R, Davies SE, Matutes E, Fegan CD et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 2005; 105: 397-404. (Pubitemid 40053111)
25. Jantunen E, Itala M, Siitonen T, Kuittinen T, Heiskanen J, Koivunen E et al. Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis. Bone Marrow Transplant 2008; 41: 239-244. (Pubitemid 351260377)
26. Stone RM, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe SN et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2535-2542. (Pubitemid 24379636)
27. Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce E et al. Outcome in patients with myelodys-plastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3128-3135. (Pubitemid 29470642)
28. Gilliland DG, Gribben JG. Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation. Biol Blood Marrow Transplant 2002; 14: 10-18.
29. Bosch F, Ferrer A, Lopez-Guillermo A, Gine E, Bellosillo B, Villamor N et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002; 119: 976-984. (Pubitemid 35463822)
30. Esteve J, Villamor N, Colomer D, Cervantes F, Campo E, Carreras E et al. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia 2001; 15: 445-451. (Pubitemid 32243779)
31. Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A et al. Eradication of minimal residual disease in B-Cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971-2979. (Pubitemid 46224116)
32. Montserrat E. Treatment of chronic lymphocytic leukaemia: achieving minimal residual disease-negative as a goal. J Clin Oncol 2005; 23: 2884-2885. (Pubitemid 46224104)
33. Dreger P, Ritgen M, Bottcher S, Schmitz N, Kneba M. The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukaemia: is achievement of molecular remission worthwhile? Leukemia 2005; 19: 1135-1138. (Pubitemid 40945994)
34. Tam CS, O'Brien S, WIerda W, Kantarjian H, Wen S, Do KA et al. Long-term results of the fludarabine, cyclopho-sphamide and rituximab regimen as initial therapy of chronic lymphocytic leukaemia. Blood 2008; 112: 975-980.